BioNTech, CureVac and Co. Patent Suspensions Threaten Germany's Booming Biotech Industry

With their next-generation mRNA vaccines, the German companies BioNTech and CureVac are at the forefront of pharmaceutical innovation. But U.S. President Joe Biden's plan to suspend patent protections is threatening that position.
BioNTech founders Özlem Türeci and Uğur Şahin: Their company is also working on vaccines against the flu and cancer.

BioNTech founders Özlem Türeci and Uğur Şahin: Their company is also working on vaccines against the flu and cancer.

Foto:

Ramon Haindl

DER SPIEGEL 19/2021
SPIEGEL International
Curevac Co-founder Ingmar Hoerr: A significant Made-in-Germany component.

Curevac Co-founder Ingmar Hoerr: A significant Made-in-Germany component.

Foto: Sebastian Gollnow / dpa
Workers at the BioNTech factory in Marburg

Workers at the BioNTech factory in Marburg

Foto: Thomas Lohnes / AFP
"Our situation would look quite a bit different if we had had a strong partner on board by last summer."

CureVac CEO Franz-Werner Haas